<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:6pt Arial, sans-serif; }
 .font1 { font:7pt Arial, sans-serif; }
 .font2 { font:8pt Arial, sans-serif; }
 .font3 { font:9pt Arial, sans-serif; }
 .font4 { font:12pt Arial, sans-serif; }
 .font5 { font:19pt Arial, sans-serif; }
 .font6 { font:8pt Times New Roman, serif; }
 .font7 { font:9pt Times New Roman, serif; }
 .font8 { font:10pt Times New Roman, serif; }
 .font9 { font:25pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font9">J.P. Morgan</span></p>
<p><span class="font3" style="font-weight:bold;">Asia Pacific Equity Research </span><span class="font0">17 </span><span class="font2">August </span><span class="font0">2023</span></p><a name="caption1"></a>
<h6><a name="bookmark0"></a><span class="font5" style="font-weight:bold;"><a name="bookmark1"></a>Amcor, Amcor PLC</span></h6>
<p><span class="font4">A tale of two halves; all eyes on 2H24 as demand and de-stocking dominates; retain OW</span></p>
<p><span class="font8">AMC’s FY23 result saw improved priceZmix (+c.5%) largely offset by muted volumes (3%) as consumer demand slowed and destocking continued. Of particular interest this time was the softening in priority sectors (healthcare/ petcare) in Flexibles and hot fill beverages (-6% yoy) in Rigids during 4Q23 which for the latter represents the seasonally strongest quarter. Current trends are set to prevail for much of 1H24 with management anticipating up to a low double-digit decline in EPS for the period before a 2H24 recovery where it is hoped cycling the Russian business closure, the step-up in net interest costs, the realisation of cost-out and input cost moderation starts to aid the bottom line. In all, this manifests into slightly softer EPS growth of US67-71 cps yoy (FY23 US73cps). We make c.2-3% EBIT cuts over FY23-24e with our PT (SOTPZDCF) falling c.4% to A$ 15.30 (was A$ 16.00). Remain Overweight.</span></p>
<div>
<p><span class="font2" style="font-weight:bold;">Australia</span></p>
<p><span class="font3" style="font-weight:bold;">Transport &amp;&nbsp;Infrastructure</span></p>
<p><span class="font2" style="font-weight:bold;">Anthony Longo <sup>AC</sup></span></p>
<p><span class="font0">(61-3) 9633-4030</span></p>
<p><a href="mailto:anthony.x.longo@jpmorgan.com"><span class="font0">anthony.x.longo@jpmorgan.com</span></a></p>
<p><span class="font0">Bloomberg JPMA LONGO &lt;GO&gt;</span></p>
<p><span class="font2" style="font-weight:bold;">Ross Chapman</span></p>
<p><span class="font0">(61-2) 9003-7081</span></p>
<p><a href="mailto:ross.chapman@jpmorgan.com"><span class="font0">ross.chapman@jpmorgan.com</span></a></p>
<p><span class="font0">J.P. Morgan Securities Australia Limited</span></p>
</div><br clear="all">
<ul style="list-style:none;"><li>
<p><span class="font6" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;FY23 result matches downgraded guidance. </span><span class="font8">Revenue was +c.l% yoy but higher costs saw EBIT -6% yoy, but c.2% ahead of our estimates. Net interest increased significantly to US$260m given balance sheet leverage and higher rates and matched guidance (of US$260-270m) partially offset by lower taxes which saw underlying NPAT -11% yoy (+3% vs. JPMe). FY23 DPS of US49cps was ahead of our estimates.</span></p></li>
<li>
<p><span class="font6" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Segments largely in line but Rigids weakest. </span><span class="font8">In actual FX, Rigids (FY23 RevZEBIT +4%/-8% yoy) largely matched our estimates. Nth American beverage volumes were -c.6% inFY23 (but hot fill vols matched the pep) with consumer demand reducing and destocking presenting but masked by new business wins. Flexibles (RevZEBIT 0%/-6% yoy in Actual FX) matched our estimates. Despite posting strong growth yoy, priority segments (incl. healthcare, pharmaceutical and pet care markets saw volumes contract during 4Q23). In all, 4Q23 volumes in Flexibles/Rigids were -7%/-6% yoy, respectively, as softer demand conditions remained.</span></p></li>
<li>
<p><span class="font6" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Outlook &amp;&nbsp;guidance. </span><span class="font8">FY24 adj. EPS guidance of US67-71cps comprises a </span><span class="font7" style="font-style:italic;">‘high single digit to low double digit’ decline</span><span class="font8"> in 1H24 before a recovery in 2H24, anticipating </span><span class="font7" style="font-style:italic;">‘midsingle digit</span><span class="font8">' constant FX growth in 2H24. Net interest expectations of $320-340m were higher than our expectations (FY24e: US $285m). FY24 Adj. FCF of US$850-950m (FY24e: A$861m) is expected.</span></p></li>
<li>
<p><span class="font6" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Earnings &amp;&nbsp;valuation; retain OW. </span><span class="font8">Rebasing for the FY23 result drives c.2% EBIT cuts over F Y24-25e but more pronounced cuts at EPS of c.6-7% to reflect net interest guidance (while 65% fixed, net interest guidance of US$320-340m was ahead of our estimates before today). Given our earnings changes our PT (SOTP/PE rel.) is -c.4% to A$ 15.30 (was A$ 16.00); retain OW.</span></p></li></ul>
<p><span class="font2" style="font-weight:bold;">Equity Ratings and Price Targets</span></p>
<table border="1">
<tr><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Company</span></p></td><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">Mkt Cap Price &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="font1" style="font-weight:bold;text-decoration:underline;">Rating</span><span class="font1" style="font-weight:bold;">__</span><span class="font1" style="font-weight:bold;text-decoration:underline;">Price Target</span><span class="font1" style="font-weight:bold;">___________</span></p>
<p><span class="font1" style="font-weight:bold;">Ticker &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;($mn) CCY &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Price Cur Prev &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cur o<sub>a</sub>t<sub>e</sub> Prev End Date</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">Amcor</span></p>
<p><span class="font1">Amcor PLC</span></p></td><td style="vertical-align:top;">
<p><span class="font1">AMCRUS &nbsp;&nbsp;&nbsp;&nbsp;13,846.29 &nbsp;&nbsp;USD &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.41 &nbsp;&nbsp;&nbsp;&nbsp;OW &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;n/c &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.80 Aug-24 &nbsp;&nbsp;10.70 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;n/c</span></p>
<p><span class="font1">AMC AU &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13,394.81 &nbsp;&nbsp;&nbsp;AUD &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.17 &nbsp;&nbsp;&nbsp;&nbsp;OW &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;n/c &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.30 Aug-24 &nbsp;&nbsp;&nbsp;16.00 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;n/c</span></p></td></tr>
</table>
<p><span class="font0">Source: Company data, Bloomberg Finance L.P., J.P. Morgan estimates, n/c = no change.All prices as of 16 Aug 23 except for AMC AU [17 Aug 23]</span></p>
<p><span class="font3" style="font-weight:bold;">See page 14 for analyst certification and important disclosures, including non-US analyst disclosures.</span></p>
<p><span class="font2">J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of Interest that could affect the objectivity of this report. Investors should consider this report as only a single factor In making their Investment decision.</span></p>
<p><a href="http://www.jpmorganmarkets.com"><span class="font8" style="font-weight:bold;">www.jpmorganmarkets.com</span></a></p>
</body>
</html>